Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme (Q44357042)

2 December 2017

title

Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme (English)

1 reference

2 December 2017

2

Twelves CJ

1 reference

2 December 2017

Dobbs NA

1

1 reference

2 December 2017

Gregory W

3

1 reference

2 December 2017

Cruickshanka C

4

1 reference

2 December 2017

Richards MA

5

1 reference

2 December 2017

Rubens RD

6

1 reference

2 December 2017

publication date

1 March 2003

1 reference

European Journal of Cancer

2 December 2017

published in

1 reference

2 December 2017

volume

39

1 reference

2 December 2017

issue

5

1 reference

2 December 2017

page(s)

580-586

1 reference

Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

What is the effect of adjusting epirubicin doses for body surface area?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Measurement of epidoxorubicin and its metabolites by high-performance liquid chromatography using an advanced automated sample processor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

STRIPE: an interactive computer program for the analysis of drug pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Epirubicin in breast cancer patients with liver metastases and abnormal liver biochemistry: Initial weekly treatment followed by rescheduling and intensification

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Cellular and plasma pharmacokinetics of weekly 20-mg 4'-epi-adriamycin bolus injection in patients with advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Variability in the pharmacokinetics of epirubicin: a population analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Doxorubicin clearance in the obese

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900669-X

7 January 2021

10.1016/S0959-8049(02)00669-X

Identifiers

DOI

1 reference

2 December 2017

1 reference